Newly approved DMARDs can appear less safe due to ‘channeling’ phenomenon

Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases. “Currently, there are safety concerns regarding treatment with Janus kinase inhibitors for patients with RA that limit their clinical use,” Viktor